提出日:
報告基準日:
ADMISSION OF FURTHER SECURITIES TO TRADING
提出日:
報告基準日:
TOTAL VOTING RIGHTS
提出日:
報告基準日:
ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING
提出日:
報告基準日:
ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC
提出日:
報告基準日:
DIRECTORATE CHANGE
提出日:
報告基準日:
ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY
提出日:
報告基準日:
TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG
提出日:
報告基準日:
TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS
提出日:
報告基準日:
ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING
提出日:
報告基準日:
DIRECTOR/PDMR SHAREHOLDING
提出日:
報告基準日:
ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER
提出日:
報告基準日:
UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL
提出日:
報告基準日:
TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG
提出日:
報告基準日:
PRIMARY DOCUMENT
提出日:
報告基準日:
ADMISSION OF FURTHER SECURITIES TO TRADING
提出日:
報告基準日:
TOTAL VOTING RIGHTS
提出日:
報告基準日:
DATROWAY APPROVED IN EU FOR TNBC
提出日:
報告基準日:
FORM 6-K
提出日:
報告基準日:
UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA
提出日:
報告基準日:
SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS
提出日:
報告基準日:
ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER
提出日:
報告基準日:
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR
提出日:
報告基準日:
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL
提出日:
報告基準日:
OWNERSHIP DOCUMENT
提出日:
報告基準日:
ADMISSION OF FURTHER SECURITIES TO TRADING
提出日:
報告基準日:
TOTAL VOTING RIGHTS
提出日:
報告基準日:
ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS
提出日:
報告基準日:
DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC
提出日:
報告基準日:
OWNERSHIP DOCUMENT
提出日:
報告基準日:
TRUQAP APPROVED IN US FOR PROSTATE CANCER
提出日:
報告基準日:
ADMISSION OF FURTHER SECURITIES TO TRADING
提出日:
報告基準日:
TOTAL VOTING RIGHTS
提出日:
報告基準日:
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER
提出日:
報告基準日:
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED
提出日:
報告基準日:
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC
提出日:
報告基準日:
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS
提出日:
報告基準日:
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU
提出日:
報告基準日:
OWNERSHIP DOCUMENT
提出日:
報告基準日:
DIRECTOR/PDMR SHAREHOLDING
提出日:
報告基準日:
BAXFENDY APPROVED IN THE US FOR HYPERTENSION